Skip to content

prophy_effects_sotro_molnup

Organisation:
Bennett Institute
Project:
Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19
View logs

Workspace information

Branch
main
Created
Created by
Qing Wen

This is an OpenSAFELY workspace. It represents a working directory for the 91 - Coverage, effectiveness and safety of neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 project on all of the secure services ("backends") supported by OpenSAFELY.

On each backend, the directory includes code from the repository, and the results of running it against real data ("jobs"). Researchers can request jobs are run from this page.

Workspace purpose

Research on the prophylactic effects of Sotrovimab and Molnupiravir focuses on non-hospitalised patients during their first recorded COVID-19 infection. It aims to evaluate and compare the risk of hospitalisation and death due to COVID-19 among high-risk individuals from 60 days after receiving treatment and extending a further six months, serving as the primary outcomes.

Releases

Reports

  • No reports added to this workspace